Business Description
Allergy Therapeutics PLC
ISIN : GB00B02LCQ05
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.37 | |||||
Equity-to-Asset | 0.38 | |||||
Debt-to-Equity | 0.37 | |||||
Debt-to-EBITDA | -0.25 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -2.39 | |||||
Beneish M-Score | -4.04 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -8.5 | |||||
3-Year Book Growth Rate | -64.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 58.67 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.38 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 100 | |||||
9-Day RSI | 100 | |||||
14-Day RSI | 100 | |||||
6-1 Month Momentum % | 200 | |||||
12-1 Month Momentum % | -65.71 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.4 | |||||
Quick Ratio | 0.93 | |||||
Cash Ratio | 0.54 | |||||
Days Inventory | 165.86 | |||||
Days Sales Outstanding | 54.82 | |||||
Days Payable | 185.21 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | -27.19 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 52.54 | |||||
Operating Margin % | -72.92 | |||||
Net Margin % | -94.29 | |||||
FCF Margin % | -67.27 | |||||
ROE % | -226.59 | |||||
ROA % | -72.62 | |||||
ROIC % | -96.92 | |||||
3-Year ROIIC % | -4606.95 | |||||
ROC (Joel Greenblatt) % | -170.16 | |||||
ROCE % | -88.53 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.99 | |||||
PB Ratio | 6.75 | |||||
Price-to-Tangible-Book | 6 | |||||
EV-to-EBIT | -4.38 | |||||
EV-to-Forward-EBIT | -8.71 | |||||
EV-to-EBITDA | -4.85 | |||||
EV-to-Forward-EBITDA | -11.37 | |||||
EV-to-Revenue | 3.56 | |||||
EV-to-Forward-Revenue | 3.11 | |||||
EV-to-FCF | -5.28 | |||||
Price-to-Median-PS-Value | 0.21 | |||||
Earnings Yield (Greenblatt) % | -22.83 | |||||
FCF Yield % | -18.57 | |||||
Forward Rate of Return (Yacktman) % | -3.93 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:AGYTF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Allergy Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 67.352 | ||
EPS (TTM) ($) | -0.072 | ||
Beta | 1.91 | ||
Volatility % | 245.76 | ||
14-Day RSI | 100 | ||
14-Day ATR ($) | 0.000096 | ||
20-Day SMA ($) | 0.06 | ||
12-1 Month Momentum % | -65.71 | ||
52-Week Range ($) | 0.01 - 0.175 | ||
Shares Outstanding (Mil) | 4,766.44 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Allergy Therapeutics PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Allergy Therapeutics PLC Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Allergy Therapeutics PLC Frequently Asked Questions
What is Allergy Therapeutics PLC(AGYTF)'s stock price today?
When is next earnings date of Allergy Therapeutics PLC(AGYTF)?
Does Allergy Therapeutics PLC(AGYTF) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |